The use of platelet-rich fibrin in the surgical treatment of medication-related osteonecrosis of the jaw: 40 patients prospective study
| Authors | |
|---|---|
| Year of publication | 2021 |
| Type | Article in Periodical |
| Magazine / Source | Biomedical Papers |
| MU Faculty or unit | |
| Citation | |
| Web | https://biomed.papers.upol.cz/artkey/bio-202103-0013_the-use-of-platelet-rich-fibrin-in-the-surgical-treatment-of-medication-related-osteonecrosis-of-the-jaw-40-pa.php?back=%2Fsearch.php%3Fquery%3DZelinka%2Bin%253Aauth%2Bname%2Bkey%2Babstr%26sfrom%3D0%26 |
| Doi | http://dx.doi.org/10.5507/bp.2020.023 |
| Keywords | medication related osteonecrosis of the jawplatelet rich fibrinsurgical treatment |
| Description | Medication-related osteonecrosis of the jaw (MRONJ) is defined as exposed bone in the maxillofacial region persisting for more than eight weeks in patients who are or were treated with antiresorptive or antiangiogenic agents and had no radiation therapy to the craniofacial region or obvious metastatic disease of the jaws. It is a recognised side effect of antiresorptive or antiangiogenic medication. To date, there is no specific gold standard treatment for MRONJ cases. The aim of this study was to evaluate the successful rate of surgical treatment with adjuvant local application of platelet rich fibrin. |